Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, ...

Cytokinetics has been a top biotech takeover candidate for some time, thanks to blockbuster speculation about its lead drug aficamten, but a $1 billion-plus set of financing deals shows it is ...

The CEO of Cytokinetics says the company is not for sale. That doesn't mean it would turn away potential suitors.

Cytokinetics should hear back from the FDA next September about its marketing application for aficamten, which is vying to become the first rival to Bristol-Myers Squibb's fast-growing Camzyos for ...

The company's lead candidate, aficamten, has been advancing steadily through the regulatory process. Cytokinetics is on track to complete its New Drug Application (NDA) submission to the U.S. Food ...

Cytokinetics is on track to submit a New Drug Application (NDA) for aficamten in obstructive HCM (oHCM) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2024. This timeline ...

CEO Robert Blum is “very clear” that the company, which is on track for U.S. approval in September for aficamten to treat a ...

Royalty Pharma said its decision follows feedback from investors that the current structure made it difficult to ... capital for 14 experimental treatments, including Cytokinetics' heart disease drug ...

PDUFA Target Action Date for Aficamten Set for September 26, 2025;Commercial Launch Preparations Underway for First Potential Approval Five-Year Aspirations Outline Corporate Strategies to ...

Cytokinetics is on track to submit a New Drug Application (NDA) for aficamten in obstructive HCM (oHCM) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2024. This timeline is ...

The company's lead candidate, aficamten, has been advancing steadily through the regulatory process. Cytokinetics is on track to complete its New Drug Application (NDA) submission to the U.S. Food and ...